Haemonetics Corporation Reaffirms FY 2013 Guidance; Comments On FY 2014 Revenue Guidance; Issues FY 2014 Guidance Above Analysts' Estimates

Haemonetics Corporation announced that for fiscal 2013, it expects organic revenue growth to be approximately 4%-6% and adjusted earnings per share (EPS) between $3.30-$3.40. The Company reported GAAP net revenue of $727.8 million in fiscal 2013. For fiscal 2014, it expects organic revenue growth is expected to approximate 5%-7% and adjusted earnings per share is $3.90-$4.10. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $766.6 million and EPS of $3.35 for fiscal 2013; revenue of $812.6 million and EPS of $3.82 for fiscal 2014.